New pill targets Tough-to-Treat lung cancer in groundbreaking trial
NCT ID NCT07491497
Summary
This study is testing a new oral medication called TRI-611 for adults with advanced ALK-positive non-small cell lung cancer. The first part aims to find a safe and effective dose, while the second part will see how well the drug works in different groups of patients based on their prior treatments. Participants will take the pill continuously for as long as it helps control their cancer and is well-tolerated.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALK-POSITIVE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Memorial Sloan-Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
Contact
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
Contact
-
Taylor Cancer Research Center
RECRUITINGMaumee, Ohio, 43537, United States
Contact
Conditions
Explore the condition pages connected to this study.